"I think industry is dedicated to that. We certainly have a pivotal role I think in that space," Vered Caplan, the CEO of the company, said in an interview on Yahoo's Midday Movers..
She added: "If you look at the hospitals that are involved, the research institutes, they are all looking for a way from the science perspective how do we get the costs down."
US officials have criticized drug makers for the expensive drugs they make.
Shares of Orgenesis closed on Friday up 1.26% to $6.45.
Caplan said there is a technology issue where investments must be made in the development of cutting-edge drugs.
"Let us look at the drugs we make. These are the next-generation," she said.
She said women are "very well accepted" when asked about the fact that there are very few women in the top ranks of companies in the country.
Orgenesis is a manufacturer, service provider and developer of advanced cell therapies.
The company is based in Germantown, Maryland.
Reporting by Rene Pastor, contactable on [email protected]